Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Baltimore, Maryland 21225


The purpose of this study is to determine the safety and tolerability of CoFactor in healthy subjects.


Inclusion Criteria: - Males and Females age 18-65 inclusive at screening. - Subject has to agree to practice abstinence or medically accepted contraception and not to participate in sperm donation or in vitro fertilization. - Body Mass Index in the range of 18 to 30 kg/m2 and body weight of 45 to 95 kg. - Subject must be healthy as determined by the investigator on the basis of screening evaluations. - Subject must be nonsmoker or smoker of fewer than 10 cigarettes per day as determined by history. Must be able to abstain from smoking during the in-clinic stay. Exclusion Criteria: - Presence of clinically significant illness within 21 days prior to dosing, viral or bacterial infection, or documented drug allergies that may affect subject's safety during the study. - Laboratory or clinical evidence suggestive of disease. - Clinically significant or predisposing disorder that may interfere with the absorption, distribution, metabolism and/or excretion of drugs. - History of drug abuse within 1 year of dosing and/or admitted alcohol abuse or history of alcohol use that may interfere with the ability to comply. - Pregnant, lactating, or positive pregnancy test. - Clinically significant electrocardiogram abnormalities. - History of positive test for hepatitis B or C, or HIV. - Positive findings of urine narcotic screen. - History of drug allergy.

Study is Available At:

Original ID:

CoFactor 510-20



Secondary ID:

Study Acronym:

Brief Title:

A Clinical Trial of CoFactor Formulations and Leucovorin Administered Intravenously in Healthy, Adult Subjects.

Official Title:

A Single Dose, Within Subject, 3 Period, Pharmacokinetic Bridging Study of CoFactor Formulations and of Leucovorin Administered Intravenously in Healthy, Adult Subjects.

Overall Status:


Study Phase:

Phase 1



Minimum Age:

18 Years

Maximum Age:

65 Years

Quick Facts

Healthy Volunteers
Oversight Has DMC
Study Is FDA Regulated
Study Is Section 801
Has Expanded Access

Study Source:

Adventrx Pharmaceuticals

Oversight Authority:

United States: Food and Drug Administration

Reasons Why Stopped:

Study Type:


Study Design:

Allocation: Randomized, Endpoint Classification:

Number of Arms:


Number of Groups:


Total Enrollment:


Enrollment Type:


Overall Contact Information

Official Name:Ronald Goldwater, MD
Principal Investigator
Parexel International - Baltimore CPRU

Study Dates

Start Date:April 2008
Completion Date:May 2008
Completion Type:Actual
Primary Completion Date:May 2008
Primary Completion Type:Actual
Verification Date:May 2009
Last Changed Date:May 27, 2009
First Received Date:April 18, 2008

Study Outcomes

Outcome Type:Secondary Outcome
Measure:To measure the 5,10 methylenetetrahydrofolic acid levels after CoFactor and leucovorin administration
Safety Issues:False
Outcome Type:Primary Outcome
Measure:Pharmacokinetic profile of CoFactor formulations in healthy adult subjects.
Safety Issues:False

Study Interventions

Intervention Type:Drug
Arm Name:1
Other Name:ANX-510
Intervention Type:Drug
Arm Name:3

Study Arms

Study Arm Type:Active Comparator
Arm Name:3
Study Arm Type:Experimental
Arm Name:2
Study Arm Type:Experimental
Arm Name:1

Study Agencies

Agency Class:Industry
Agency Type:Lead Sponsor
Agency Name:Adventrx Pharmaceuticals

Sample and Retention Information

There are no available Sample and Retention Information

Study References

There are no available Study References

Data Source: ClinicalTrials.gov

Date Processed: January 21, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

This study is not currently recruiting Study Participants. The form below is not enabled.